Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGL | P06737 | 1/20 | 0.55 |
| ▸ | SLC5A2 | P31639 | 8/20 | 0.49 |
| ▸ | CD209 | Q9NNX6 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8772876 | 1.00 | PYGL (0.55) | PYGLSLC5A2CD209 | |
| SCHEMBL8766883 | 0.88 | EPHX1 (0.50) | PYGLCD209 | |
| SCHEMBL25605620 | 0.86 | PYGL (0.46) | PYGLSLC5A2CD209 | |
| SCHEMBL3759096 | 0.86 | PYGL (0.52) | PYGLSLC5A2CD209 | |
| SCHEMBL23797741 | 0.83 | LGALS3 (0.47) | PYGLSLC5A2CD209 | |
| SCHEMBL23547663 | 0.83 | LGALS3 (0.47) | PYGLSLC5A2CD209 | |
| SCHEMBL2917657 | 0.78 | SLC5A2 (0.57) | PYGLSLC5A2 | |
| SCHEMBL27843034 | 0.78 | EPHX1 (0.44) | PYGLCD209 | |
| SCHEMBL440403 | 0.77 | SLC5A2 (0.59) | PYGLSLC5A2 | |
| SCHEMBL6542524 | 0.77 | SLC5A2 (0.59) | PYGLSLC5A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 119 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0416817-B1 | Amplification processes | ZENECA LTD (GB) | 1996-10-16 | — | — | EP | claimed |
| US-5525494-A | Amplification processes | ZENECA LIMITED (GB) | 1996-06-11 | — | — | US | claimed |
| EP-0416817-A2 | Amplification processes | ZENECA LIMITED (GB) | 1991-03-13 | — | — | EP | claimed |
| US-20260103744-A1 | CHIMERIC PRIMERS WITH HAIRPIN CONFORMATIONS AND METHODS OF USING SAME | LUMINEX CORPORATION (US) | 2026-04-16 | — | — | US | disclosed |
| US-12473586-B2 | Chimeric primers with hairpin conformations and methods of using same | LUMINEX CORPORATION (US) | 2025-11-18 | — | — | US | disclosed |
| US-20240318233-A1 | CHIMERIC PRIMERS WITH HAIRPIN CONFORMATIONS AND METHODS OF USING SAME | LUMINEX CORPORATION (US) | 2024-09-26 | — | — | US | disclosed |
| US-11884965-B2 | Chimeric primers with hairpin conformations and methods of using same | LUMINEX CORPORATION (US) | 2024-01-30 | — | — | US | disclosed |
| US-11702699-B2 | Detection of nucleotide variation on target nucleic acid sequence | SEEGENE, INC. (KR) | 2023-07-18 | — | — | US | disclosed |
| EP-3022319-B1 | DETECTION OF TARGET NUCLEIC ACID SEQUENCE BY PTO CLEAVAGE AND EXTENSION-DEPENDENT IMMOBILIZED OLIGONUCLEOTIDE HYBRIDIZATION | SEEGENE INC (KR) | 2023-05-17 | — | — | EP | disclosed |
| US-11447814-B2 | Detection of target nucleic acid sequence on solid phase by PTO cleavage and extension using HCTO assay | SEEGENE, INC. (KR) | 2022-09-20 | — | — | US | disclosed |
| US-20220251633-A1 | CHIMERIC PRIMERS WITH HAIRPIN CONFORMATIONS AND METHODS OF USING SAME | LUMINEX CORPORATION (US) | 2022-08-11 | — | — | US | disclosed |
| EP-2099930-A2 | SYSTEMS AND METHODS FOR MULTIPLEX ANALYSIS OF PCR IN REAL TIME | Luminex Corporation (US) | 2009-09-16 | — | — | EP | disclosed |
| WO-2009074882-A2 | ONE-STEP TARGET DETECTION ASSAY | LUMINEX MOLECULAR DIAGNOSTICS, INC. (US) | 2009-06-18 | — | — | WO | disclosed |
| US-20090148849-A1 | ONE-STEP TARGET DETECTION ASSAY | LUMINEX MOLECULAR DIAGNOSTICS (CA) | 2009-06-11 | — | — | US | disclosed |
| US-20090136956-A1 | Use of Dual-Tags for the Evaluation of Genomic Variable Repeat Regions | LUMINEX MOLECULAR DIAGNOSTICS (CA) | 2009-05-28 | — | — | US | disclosed |
| US-20080305481-A1 | SYSTEMS AND METHODS FOR MULTIPLEX ANALYSIS OF PCR IN REAL TIME | LUMINEX CORPORATION | 2008-12-11 | — | — | US | disclosed |
| WO-2008074023-A2 | SYSTEMS AND METHODS FOR MULTIPLEX ANALYSIS OF PCR IN REAL TIME | LUMINEX CORPORATION (US) | 2008-06-19 | — | — | WO | disclosed |
| EP-0416817-B1 | Amplification processes | ZENECA LTD (GB) | 1996-10-16 | — | — | EP | disclosed |
| US-5525494-A | Amplification processes | ZENECA LIMITED (GB) | 1996-06-11 | — | — | US | disclosed |
| EP-0416817-A2 | Amplification processes | ZENECA LIMITED (GB) | 1991-03-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260103744-A1 | CHIMERIC PRIMERS WITH HAIRPIN CONFORMATIONS AND METHODS OF USING SAME | MICA, RNGTT, DNMT3A | PYGL 4436/4885SLC5A2 2401/4885CD209 816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.